HM2014-26 DT2219 Immunotoxin for the Treatment of Relapsed or Refractory CD19 (+) and/or CD 22 (+) B-lineage Leukemia or Lymphoma

Trial Profile

HM2014-26 DT2219 Immunotoxin for the Treatment of Relapsed or Refractory CD19 (+) and/or CD 22 (+) B-lineage Leukemia or Lymphoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs DT2219ARL (Primary)
  • Indications B cell lymphoma; B-cell leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 02 Aug 2017 According to a GT Biopharma media release, four patients have been enrolled in the phase II part of this trial. Results of the Phase 2 trial are expected to be released in the first quarter of 2018.
    • 26 Jul 2017 Planned End Date changed from 1 Jun 2018 to 1 Jun 2019.
    • 26 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top